Skip to content
Clinical Trials – home
GreeceBack to Greece

Clinical trials in Peristeri – page 27

1 033 clinical trials in Peristeri, Greece. Every trial is listed in the EU Clinical Trials Register and updated daily.

GreeceOur site in GreeceΚλινικεσΔοκιμεσ.gr(opens in a new tab)
Peristeri at a glance
1 033
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 033 trials in Peristeri

Open in trial search

Continued Access Study for Patients with Severe Hemophilia A Using Efanesoctocog Alfa

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Efanesoctocog Alfa
  • Sponsor:Swedish Orphan Biovitrum AB (publ)

Study on Posaconazole for Treating Fungal Infections in Children Under 2 Years

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:0–17 years
  • Substances:Posaconazole
  • Sponsor:Merck Sharp & Dohme LLC

Study on the Safety and Effectiveness of Zilovertamab Vedotin for Children and Young Adults with Blood Cancers or Solid Tumors

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years
  • Substances:Zilovertamab Vedotin
  • Sponsor:Merck Sharp & Dohme LLC

Study on Diacerein 1% Ointment for Treating Generalized Epidermolysis Bullosa Simplex in Patients Aged 6 Months and Older

Investigational
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years
  • Substances:Diacerein
  • Sponsor:Twi Biotechnology Inc.

Study Comparing Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone with Ciltacabtagene Autoleucel or Stem Cell Transplant for Newly Diagnosed Multiple Myeloma Patients

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Study Comparing Elranatamab to Drug Combinations for Patients with Relapsed/Refractory Multiple Myeloma After Anti-CD38 Therapy

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Pfizer Inc.

Study on Long-Term Safety of Tolebrutinib and Teriflunomide for Patients with Multiple Sclerosis

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Teriflunomide
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study Comparing MK-2870 and Pembrolizumab with Chemotherapy for Patients with Advanced Hormone Receptor Positive Breast Cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Study on the Safety and Effects of OBT076 and Balstilimab in Patients with Recurrent or Metastatic CD205-Positive Solid Tumors

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Balstilimab
  • Sponsor:Oxford Biotherapeutics Limited

Nephroblastoma

Recruiting

Study Comparing Vincristine, Actinomycin-D, and Doxorubicin with Vincristine, Carboplatin, and Etoposide for Stage IV Childhood Kidney Cancer Patients

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:0–17 years
  • Substances:Carboplatin
  • Sponsor:GPOH gGmbH

Study on the Safety and Effectiveness of Linvoseltamab, Sarilumab, and Dexamethasone in Adults with Relapsed or Refractory AL Amyloidosis

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Regeneron Pharmaceuticals Inc.

Study of MK-1084 and Pembrolizumab for First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer with KRAS G12C Mutation and High PD-L1 Levels

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:MK-1084
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Greece

The busiest research cities in the country

All 48 cities in Greece

Clinical research in Peristeri

What the registry says about research in the country

01 Cardiovascular Diseases

In Peristeri, researchers are evaluating a weekly injectable agent for patients with HFpEF or HFmrEF who also have obesity, aiming to lower the combined risk of cardiovascular death and heart‑failure hospitalisations.

  • Composite cardiovascular outcome assessment
  • Weekly dosing strategy
  • Integration with standard of care
  • Focus on heart‑failure subtypes

Both studies are actively recruiting, involve 25 investigators, and seek to improve treatment options for a growing heart‑failure population.

02 Nutritional and Metabolic Diseases

Clinical trials in the city are comparing two formulations of injectable cagrilintide and a placebo, as adjuncts to diet and activity counseling, to achieve meaningful weight loss in participants with excess body weight.

  • Weight‑loss non‑inferiority testing
  • Superiority versus placebo evaluation
  • Adjunct lifestyle intervention
  • Targeting overweight and obesity

The recruiting studies involve a dedicated team of investigators and aim to expand therapeutic options for metabolic health.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.